Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy

European Journal of Cancer

Volumn 57, Issue , 2016, Pages 23-30

  Rapoport, Bernardo ^a   Schwartzberg, Lee ^b   Chasen, Martin ^c   Powers, Dan ^d   Arora, Sujata ^d   Navari, Rudolph ^e   Schnadig, Ian ^f  

^a Medical Oncology Center of Rosebank   (South Africa)

^b West Clinic   (United States)

^c William Osler Health Center   (Canada)

^d TESARO   (United States)

^e INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Medical Oncology Hematology   (United States)

Author keywords

Antiemetic; Chemotherapy induced nausea and vomiting; Multiple cycles; Neurokinin 1 receptor antagonist; Rolapitant; Subsequent cycles

Indexed keywords

8-((1-(3,5-BIS(TRIFLUOROMETHYL)PHENYL)ETHOXY)METHYL)-8-PHENYL-1,7-DIAZASPIRO(4,5)DECAN-2-ONE; ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; DEXAMETHASONE; GRANISETRON; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; SEROTONIN 3 ANTAGONIST; SPIRO COMPOUND;

ADULT; AGED; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETREATMENT; TREATMENT OUTCOME; VERY ELDERLY; VOMITING; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIEMETICS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DEXAMETHASONE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GRANISETRON; HUMANS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUROKININ-1 RECEPTOR ANTAGONISTS; ONDANSETRON; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RETREATMENT; SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS; SPIRO COMPOUNDS; TREATMENT OUTCOME; VOMITING; YOUNG ADULT;

EID: 84957596502     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2015.12.023     Document Type: Article

References (24)

1. P.J. Hesketh Chemotherapy-induced nausea and vomiting N Engl J Med 358 2008 2482 2494
2. B. Bloechl-Daum, R.R. Deuson, P. Mavros, M. Hansen, and J. Herrstedt Delayed nausea and vomiting continue to reduce patients' quality of life after highly and moderately emetogenic chemotherapy despite antiemetic treatment J Clin Oncol 24 2006 4472 4478
3. NCCN clinical practice guidelines in oncology. Antiemesis. Version 2 2015 http://www.nccn.org/professionals/physician-gls/pdf/antiemesis.pdf [accessed 05.10.15]
4. E. Basch, A.A. Prestrud, P.J. Hesketh, and et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update J Clin Oncol 29 2011 4189 4198
5. MASCC/ESMO Antiemetic Guideline 2013 http://www.mascc.org/assets/Guidelines-Tools/mascc-antiemetic-english-2014.pdf [accessed 01.09.15]
6. E. Ellebaek, and J. Herrstedt Optimizing antemetic therapy in multiple-day and multiple cycles of chemotherapy Curr Opin Support Palliat Care 2 2008 28 34
7. R. de Wit, P.I.M. Schmitz, J. Verweij, and et al. Analysis of cumulative probabilities shows that the efficacy of 5HT3 antagonist prophylaxis is not maintained J Clin Oncol 14 1996 644 651
8. R. de Wit, H. van der Berg, J. Burghouts, and et al. Initial high antiemetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles Br J Cancer 77 1998 1487 1491
9. J.A. Roscoe, G.R. Morrow, and M.S. Aapro Anticipatory nausea and vomiting Support Care Cancer 19 10 2011 1533 1538
10. R. de Wit, J. Herrstedt, B. Rapoport, and et al. Addition of the oral NK1 antagonist aprepitant to standard antiemetic provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy J Clin Oncol 21 2003 4105 4111
11. R. de Wit, J. Herrstedt, B. Rapoport, and et al. The oral NK1 antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomized, placebo-controlled phase III clinical trials Eur J Cancer 40 2004 403 410
12. J. Herrstedt, H.B. Muss, D.G. Warr, and et al. Efficacy and tolerability of aprepitant for the prevention of chemotherapy induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy Cancer 104 2005 1548 1555
13. F. Longo, G. Mansueto, V. Lapadula, and et al. Combination of aprepitant, palonosetron and dexamethasone as antiemetic prophylaxis in lung cancer patients receiving multiple cycles of cisplatin-based chemotherapy J Clin Pract 66 2012 753 757
14. R.J. Gralla, S.M. Bosnjak, A. Hontsa, and et al. A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy Ann Oncol 25 2014 1333 1339
15. J.B. McCrea, A.K. Majumdar, M.R. Goldberg, and et al. Effects of the neurokinin1 receptor antagonist aprepitant on the pharmacokinetics of dexamethasone and methylprednisolone Clin Pharmacol Ther 74 2003 17 24
16. 1 receptor antagonist, on the pharmacokinetics of midazolam, erythromycin, and dexamethasone Support Care Cancer 21 2013 2783 2791
17. VARUBI [package insert] 2015 TESARO, Inc. Waltham, MA
18. A. Poma, J. Christensen, J. Davis, and et al. Phase 1 positron emission tomography (PET) study of the receptor occupancy of rolapitant, a novel NK-1 receptor antagonist J Clin Oncol 32 Suppl 2014 Abstract e20690
19. T.J. Gan, J. Gu, N. Singla, and et al. Rolapitant for the prevention of postoperative nausea and vomiting: a prospective, double-blinded, placebo-controlled randomized trial Anesth Analg 112 2011 804 812
20. A. Poma, J. Christensen, H. Pertikis, and et al. Rolapitant and its major metabolite do not affect the pharmacokinetics of midazolam, a sensitive cytochrome P450 3A4 substrate Support Care Cancer 21 2013 S154 Abstract 441
21. L. Schwartzberg, M. Modiano, B. Rapoport, and et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of moderately emetogenic chemotherapy in cancer patients in a phase 3 randomised trial Lancet Oncol 16 2015 1071 1078
22. B.L. Rapoport, M. Chasen, C. Gridelli, and et al. Safety and efficacy assessment of rolapitant for the prevention of chemotherapy-induced nausea and vomiting following administration of cisplatin-based highly emetogenic chemotherapy in cancer patients in two randomize phase 3 trials Lancet Oncol 16 2015 1079 1089
23. B. Rapoport, D. Chua, A. Poma, and et al. Study of rolapitant, a novel, long-acting, NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) due to highly emetogenic chemotherapy (HEC) Support Care Cancer 23 2015 3281 3288
24. NCCN clinical practice guidelines in oncology. Breast cancer. Version 3 2015 http://www.nccn.org/professionals/physician-gls/pdf/breast.pdf [accessed 03.08.15]